<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053807</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-30955</org_study_id>
    <secondary_id>EORTC-30955</secondary_id>
    <nct_id>NCT00053807</nct_id>
  </id_info>
  <brief_title>Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer</brief_title>
  <official_title>Adjuvant Interleukin-2, Interferon-alpha and 5-Fluorouracil for Patients With High Risk of Relapse After Surgical Treatment for Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Interferon alfa may interfere with the growth of tumor cells. Interleukin-2 may&#xD;
      stimulate a person's white blood cells to kill tumor cells. Drugs used in chemotherapy use&#xD;
      different ways to stop tumor cells from dividing so they stop growing or die. Combining&#xD;
      interferon alfa and interleukin-2 with fluorouracil may kill any remaining tumor cells&#xD;
      following surgery. It is not yet known whether combining interferon alfa and interleukin-2&#xD;
      with fluorouracil is more effective than observation after surgery for kidney cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of combining interleukin-2,&#xD;
      interferon alfa, and fluorouracil to that of observation alone in treating patients who have&#xD;
      undergone surgery for kidney cancer and are at high risk of relapse.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the effect of adjuvant combination therapy comprising interleukin-2, interferon&#xD;
           alfa, and fluorouracil vs observation only on disease-free survival or overall survival&#xD;
           of patients with renal cell carcinoma at high risk of relapse after radical surgery.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive interleukin-2 subcutaneously (SC) on days 3, 4, and 5 of weeks 1&#xD;
           and 4 and on days 1, 3, and 5 of weeks 2 and 3. Patients also receive interferon alfa SC&#xD;
           once weekly during weeks 1 and 4 and 3 times weekly during weeks 2, 3, 5, 6, 7, and 8.&#xD;
           Patients then receive fluorouracil IV on day 1 of weeks 5, 6, 7, and 8.&#xD;
&#xD;
        -  Arm II (control arm): Patients receive no adjuvant treatment before disease progression.&#xD;
&#xD;
      Quality of life is assessed at baseline and at 2 and 6 months after randomization.&#xD;
&#xD;
      Patients are followed monthly for 3 months (arm I only), every 3 months for 1 year, every 6&#xD;
      months for 4 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 550 patients (275 per treatment arm) will be accrued for this&#xD;
      study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1998</start_date>
  <primary_completion_date type="Actual">January 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">96</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary renal cell carcinoma meeting 1 of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Stage T3b, T3c, or T4 tumor&#xD;
&#xD;
               -  Any pT stage and nodal status pN 1 or 2&#xD;
&#xD;
               -  Any pT stage and microscopic positive margins&#xD;
&#xD;
               -  Presence of any microscopic vascular invasion&#xD;
&#xD;
          -  Underwent surgical resection of primary tumor within the past month&#xD;
&#xD;
               -  Removal of clinical N+ disease required&#xD;
&#xD;
          -  No evidence of metastatic disease&#xD;
&#xD;
          -  No evidence of macroscopic residual disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  75 and under&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Liver function tests no greater than 1.25 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No prior or other concurrent malignancies that would preclude study therapy or&#xD;
             comparisons&#xD;
&#xD;
          -  No other concurrent illness that would preclude study therapy&#xD;
&#xD;
          -  No concurrent active infections requiring antibiotic therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior major organ allografts&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational drugs, agents, or devices&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pieter H. M. de Mulder, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitair Medisch Centrum St. Radboud - Nijmegen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hein van Poppel, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Gasthuisberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul A. Vasey, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beatson Institute for Cancer Research - Glasgow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Franz Josef Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>A-1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>B-9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Ghent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge - Campus St. Maarten</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>30196</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Hertogenbosch</city>
        <zip>5211 NL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Den Hoed Cancer Center at Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marmara University Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>81190</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul University School of Medicine</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson Institute for Cancer Research - Glasgow</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G61 1BD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Aitchison M, Bray CA, Van Poppel H, et al.: Final results from an EORTC (GU Group)/NCRI randomized phase III trial of adjuvant interleukin-2, interferon alpha, and 5-fluorouracil in patients with a high risk of relapse after nephrectomy for renal cell carcinoma (RCC). [Abstract] J Clin Oncol 29 (Suppl 15): A-4505, 2011.</citation>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

